References
- Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4:165rv113.
- Calderone R, Sun N, Gay-Andrieu F, et al. Antifungal drug discovery: the process and outcomes. Future Microbiol. 2014;9:791–805.
- Lai CC, Tan CK, Huang YT, et al. Current challenges in the management of invasive fungal infections. J Infect Chemother. 2008;14:77–85.
- Butts A, Krysan DJ. Antifungal drug discovery: something old and something new. PLoS Pathog. 2012;8:e1002870.
- Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science. 2012;336:647.
- Kim K, Zilbermintz L, Martchenko M. Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans. Ann Clin Microbiol Antimicrob. 2015;14:32.
- Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673–683.
- Issa NT, Byers SW, Dakshanamurthy S. Drug repurposing: translational pharmacology, chemistry, computers and the clinic. Curr Top Med Chem. 2013;13:2328–2336.
- Francesconi G, Valle AC, Passos S, et al. Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis. J Eur Acad Dermatol Venereol. 2009;23:1273–1276.
- Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol. 1992;126(Suppl 39):51–55.
- Chapman SW, Pappas P, Kauffmann C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(−1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses. 2004;47:62–68.
- Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:1255–1265.
- Shikanai-Yasuda MA, Telles Filho Fde Q, Mendes RP, et al. Guidelines in paracoccidioidomycosis. Rev Soc Bras Med Trop. 2006;39:297–310.
- Borges SR, Silva GM, Chambela Mda C, et al. Itraconazole vs. trimethoprim-sulfamethoxazole: a comparative cohort study of 200 patients with paracoccidioidomycosis. Med Mycol. 2014;52:303–310.
- Cavalcante Rde S, Sylvestre TF, Levorato AD, et al. Comparison between itraconazole and cotrimoxazole in the treatment of paracoccidiodomycosis. PLoS Negl Trop Dis. 2014;8:e2793.
- Skinner RB Jr. Imiquimod. Dermatol Clin. 2003;21:291–300.
- de Sousa Mda G, Belda W Jr., Spina R, et al. Topical application of imiquimod as a treatment for chromoblastomycosis. Clin Infect Dis. 2014;58:1734–1737.
- Widmer F, Wright LC, Obando D, et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother. 2006;50:414–421.
- Kesson AM, Bellemore MC, O’Mara TJ, et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis. 2009;48:1257–1261.
- Biswas C, Sorrell TC, Djordjevic JT, et al. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens. J Antimicrob Chemother. 2013;68:2842–2846.
- Compain F, Botterel F, Sitterle E, et al. In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp. J Med Microbiol. 2015;64:309–311.